FMED ETF Profile

Family:	Fidelity
Name:	Fidelity Disruptive Medicine ETF

Inception Date:	12-Jun-2023
Termination Date:
Investment Objective:	The fund seeks long-term growth of capital. Normally investing at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. This may include creating, providing, or contributing to new or expanded business models, value networks, pricing, and delivery of products and services Companies within the disruptive medicine theme include but are not limited to those companies that, in the Adviser's opinion, are engaged in robotic surgery, gene therapy, genomics, rare diseases, medical devices and equipment, immunotherapy, technology-based health care platforms, and consumer wellness.

Prospectus

Top 10 Holdings
BOSTON SCIENTIFIC CORP	BSX	6.4664%
SECURITIES LENDING CF	31635A303	6.0285%
NET OTHER ASSETS		-5.9960%
INSULET CORP	PODD	4.5537%
INTUITIVE SURGICAL INC	ISRG	4.5473%
UNITEDHEALTH GROUP INC	UNH	4.0576%
DANAHER CORP	DHR	3.7469%
EXACT SCIENCES CORP	EXAS	3.3982%
ARGENX SE SPONSORED ADR	ARGX	3.3389%
REGENERON PHARMACEUTICALS INC	REGN	3.0493%
	Top 10 Holdings Weight:	33.2%

Number of Holdings:	63
Shares Outstanding:	2,123,806
Total Net Assets:	54,475,620
NAV:	25.66
Net Expense Ratio:	0.50%

Asset Class:	Equities (Stocks)
Developed or Emerging:	Developed Market Funds
Country:	US
Region:
Strategy:
Currency:
Commodity:
Sector:	Healthcare
Industry:	Healthcare Providers & Services
Dividend Type:
Tax Exempt State:
Maturity Duration:
Market Cap:	Broad Market / Multi-Cap
Credit Quality:
Mortgage Bond Types:
Bond Type:
Gov't Bond Types:
Reit Type:
Leverage Direction/Factor:
Is Currency Hedged:	No
US or Ex-US:	Domestic